NVDA+2.54%AAPL+1.32%GOOGL−1.62%MSFT+0.20%AMZN−0.10%TSM+1.60%SPCX+7.79%META+0.47%
StockVS

NASDAQ · Biotechnology · USD

Korro Bio, Inc. (KRRO) Stock Analysis

Korro Bio, Inc. (KRRO) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.

Last Updated: October 21, 2026

KRRO

$9.29

−$0.15 (−1.59%)

Oct 21, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare KRRO with… →

KRRO Key Statistics

As of Oct 21, 2026
Trading
Open
$9.30
Previous Close
$9.44
Day's Range
9.22–9.77
52-Week Range
5.20–42.93
Volume
116.00K
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
2.36
Valuation
Market Cap
$136.80M
P/E Ratio
unprofitable
P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
57.43
EPS (ttm)Profit attributable to each share over the last twelve months.
−9.88
Financials (FY)
Revenue (FY)
$6.39M+181.46%
Net Income (FY)
−$117.26M
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
14.73M
1-Year Return
−77.58%
Dividend and dates
Earnings Date
November 12, 2026estimated
Avg Volume
150.42K

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

Key facts

As of October 21, 2026, KRRO closed at $9.29, −77.58% over 1 year.

Korro Bio, Inc. (KRRO) has a market capitalization of $136.80M.

In fiscal 2025, KRRO reported revenue of $6.39M.

KRRO Stock Return by Calendar Year

Korro Bio, Inc. (KRRO) return since Oct 2019: what $10,000 became

1 year
$10,000 $2,242
−77.58%
5 years
$10,000 $275
−97.25%
Since Oct 2019
$10,000 $136
−98.64%

If you had invested $10,000 in Korro Bio, Inc. (KRRO) at the close on October 3, 2019, the earliest close on record here, it would have been worth $136 at the close on October 21, 2026: −98.64% in total, −45.66% a year, over a partial period shorter than 10 years. A historical calculation from closing prices adjusted for splits and dividends, before fees and taxes.

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)+15.98%
2025−78.96%
2024−20.57%
2023−75.10%
2022−24.95%
2021−85.45%
2020+101.14%
2019 (partial year)+27.96%

As of October 21, 2026.

KRRO Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$6.39M−$117.26M−1,834.5%
2024$2.27M−$83.58M−3,680.4%
2023$0.00−$81.17M—
2022$0.00−$58.03M—
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$6.39M—−$87.34M−$117.26M−1,834.5%
2024$2.27M—−$91.91M−$83.58M−3,680.4%
2023$0.00—−$84.53M−$81.17M—
2022$0.00—−$59.00M−$58.03M—

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

KRRO Valuation vs Biotechnology Median

Median of 608 stocks
MetricKRROBiotechnology medianvs median
P/S ratio57.4313.304.3x the median

Medians across 608 Biotechnology stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of October 21, 2026.

Recent News

All 8 articles ↓

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

Korro Bio, Inc. (KRRO) is capitalised at $136.80M on the latest close. The company sits in the Healthcare sector, in the Biotechnology industry. Headcount on file is 57.

The most recent close on file for KRRO is $9.29, dated October 21, 2026. That is −$0.15 (−1.59%) against the previous close. The 52-week range on file runs from $5.20 to $42.93. The latest close sits 78.52% above that 52-week low.

Financial Health

In fiscal 2025, Korro Bio, Inc. reported revenue of $6.39M. Against the prior fiscal year total of $2.27M, that is a change of +181.46%. The same year closed with a net loss of $117.26M. Earnings per share on a trailing basis come to −9.88.

Across the 4 fiscal years on file, revenue moves from $0.00 in 2022 to $6.39M in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

No trailing P/E applies: the last reported earnings figure is negative. The price-to-sales ratio is 57.43. On price-to-sales that is 4.3 times the Biotechnology median of 13.3. 608 Biotechnology companies report these metrics, and the medians quoted come from that group.

The trailing one-year total return is −77.58%. Measured over 5 years, that is −51.25% a year compounded. The reported beta is 2.36. Daily returns over the trailing 7 years annualize to a volatility of 119.11%.

Growth & Income

The record shows no dividend for KRRO.

2026 is still running; the total return is +15.98% year to date. The strongest complete calendar year on file is 2020 at +101.14%; the weakest is 2021 at −85.45%. Of the 6 complete calendar years on file, 1 finished higher.

Peer Comparison

Korro Bio, Inc. (KRRO) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Korro Bio, Inc. KRRO $136.80M —
Vertex Pharmaceuticals Incorporated VRTX $132.95B 30.4
Moderna, Inc. MRNA $98.14B —
Regeneron Pharmaceuticals, Inc. REGN $82.95B 19.9

The Biotechnology industry average P/E ratio is 16.6x. Korro Bio, Inc. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each daily rebuild. Informational only, not financial advice. As of October 21, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$132.95B

 MRNA

Moderna, Inc.

$98.14B

 REGN

Regeneron Pharmaceuticals, Inc.

$82.95B

 ARGX

argenx SE

$55.97B

 ONC

BeOne Medicines AG

$43.97B

 RVMD

Revolution Medicines, Inc.

$41.64B
View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.13T

 JNJ

Johnson & Johnson

$621.22B

 ABBV

AbbVie Inc.

$503.27B

 UNH

UnitedHealth Group Incorporated

$374.30B

 MRK

Merck & Co., Inc.

$369.78B
View all Healthcare stocks →

About Korro Bio, Inc.

Korro Bio, Inc., a biopharmaceutical company, engages in the discovering, developing, and commercializing of genetic medicines based on editing RNA for the treatment of rare and highly prevalent diseases in the United States. The company's lead product candidate is KRRO-121 for the treatment for hyperammonemia. It uses its RNA editing platform, Oligonucleotide Promoted Editing of RNA to generate differentiated RNA editing product candidates. The company is also developing programs for Parkinson's disease, Amyotrophic lateral sclerosis, severe drug-associated anesthetics, and other pain indications. Korro Bio, Inc. has a collaboration agreement with Novo Nordisk A/S to treat cardiometabolic diseases. Korro Bio, Inc. was founded in 2018 and is based in Cambridge, Massachusetts.

Visit website →